U.S. Specialty Injectable Generics Market Size, Share & Trends Report

U.S. Specialty Injectable Generics Market Size, Share & Trends Analysis Report By Type (Drugs, Biologics), By Application (Oncology, CNS, Cardiovascular), By Distribution Channel (Hospitals, Retail Pharmacy), And Segment Forecasts, 2023 - 2030

Report ID: GVR-2-68038-014-9
Number of Pages: 100
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
  1.2. Market Definitions
1.2.1. Segment 1
  1.2.2. Segment 2
  1.2.3. Segment 3
  1.3. Research Methodology
  1.3.1. Information Analysis
  1.3.2. Market Formulation & Data Visualization
  1.3.3. Data Validation & Publishing
  1.4. Research Assumptions
  1.5. Information Procurement
  1.5.1. Primary Research
  1.6. Information or Data Analysis
  1.7. Market Formulation & Validation
  1.8. Market Model
  1.9. Global Market: CAGR Calculation
  1.10. Objective
  1.10.1. Objective 1
  1.10.2. Objective 2
Chapter 2. Executive Summary
  2.1. Market Snapshot
  2.2. Segment Snapshot
  2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
  3.1. Market Lineage Outlook
  3.1.1. Parent Market Outlook
  3.1.2. Related/Ancillary Market Outlook
  3.2. Market Dynamics
  3.2.1. Market Driver Analysis
3.2.1.1. Emerging chronic diseases patients
  3.2.1.2. Increasing number of new FDA injectable generics drugs approvals
  3.2.2. Market Restraint Analysis
  3.2.2.1. High cost of injectable
  3.3. SWOT Analysis, by Factor
  3.4. Industry Analysis- Porter’s
  3.5. Consumer Behavior Analysis
  3.6. Target Disease Population
  3.7. Regulatory Scenario
  3.8. Reimbursement Scenario
  3.9. Unmet Needs and Opportunity Analysis
  3.10. KOL Responses
Chapter 4. Type Business Analysis
  4.1. U.S. Specialty Injectable Generics Market: Type Movement Analysis
  4.2. Drugs
  4.2.1. Drugs Market, 2018 - 2030 (USD Million)
  4.3. Biologics
  4.3.1. Biologics Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
  5.1. U.S. Specialty Injectable Generics Market: Application Movement Analysis
  5.2. Oncology
  5.2.1. Oncology Market, 2018 - 2030 (USD Million)
  5.3. Cardiovascular
  5.3.1. Cardiovascular Market, 2018 - 2030 (USD Million)
  5.4. CNS
  5.4.1. CNS Market, 2018 - 2030 (USD Million)
  5.5. Infectious Diseases
  5.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  5.6. Autoimmune Disorders
  5.6.1. Autoimmune Disorders Market, 2018 - 2030 (USD Million)
  5.7. Others
  5.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
  6.1. U.S. Specialty Injectable Generics Market: Distribution Channel Movement Analysis
  6.2. Hospital
  6.2.1. Hospital Market, 2018 - 2030 (USD Million)
  6.3. Retail Pharmacy
  6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  6.4. Others
  6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
  7.1. Company Categorization
  7.2. Strategy Mapping
  7.3. Company Market Share Analysis, 2022
  7.4. Company Profiles/Listing
  7.4.1. Pfizer, Inc.
  7.4.1.1. Overview
  7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.1.3. Product Benchmarking
  7.4.1.4. Strategic Initiatives
  7.4.2. Teva Pharmaceutical Industries Ltd.
  7.4.2.1. Overview
  7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.2.3. Product Benchmarking
  7.4.2.4. Strategic Initiatives
  7.4.3. Baxter International
  7.4.3.1. Overview
  7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.3.3. Product Benchmarking
  7.4.3.4. Strategic Initiatives
  7.4.4. Novartis AG
  7.4.4.1. Overview
  7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.4.3. Product Benchmarking
  7.4.4.4. Strategic Initiatives
  7.4.5. Fresenius SE & Co. KGaA
  7.4.5.1. Overview
  7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.5.3. Product Benchmarking
  7.4.5.4. Strategic Initiatives
  7.4.6. Par Pharmaceutical
  7.4.6.1. Overview
  7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.6.3. Product Benchmarking
  7.4.6.4. Strategic Initiatives
  7.4.7. Hikma Pharmaceuticals PLC
  7.4.7.1. Overview
  7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.7.3. Product Benchmarking
  7.4.7.4. Strategic Initiatives
  7.4.8. Dr. Reddy's Laboratories
  7.4.8.1. Overview
  7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.8.3. Product Benchmarking
  7.4.8.4. Strategic Initiatives
  7.4.9. Sagent Pharmaceuticals, Inc.
  7.4.9.1. Overview
  7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.9.3. Product Benchmarking
  7.4.9.4. Strategic Initiatives
  7.4.10. Mylan N.V.
  7.4.10.1. Overview
  7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  7.4.10.3. Product Benchmarking
  7.4.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Specialty Injectable Generics market revenue estimated and forecast, by type, 2018 - 2030 (USD million)
Table 4 U.S. Specialty Injectable Generics market revenue estimated and forecast, by application, 2018 - 2030 (USD million)
Table 5 U.S. Specialty Injectable Generics market revenue estimated and forecast, by distribution channel, 2018 - 2030 (USD million)
Table 6 Company market share, 2022

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 U.S. Specialty Injectable Generics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 U.S. Specialty Injectable Generics market: Type outlook and key takeaways
Fig. 15 U.S. Specialty Injectable Generics market: Type movement analysis & market share 2022 & 2030
Fig. 16 Drugs market, 2018 - 2030 (USD Million)
Fig. 17 Biologics market, 2018 - 2030 (USD Million)
Fig. 18 U.S. Specialty Injectable Generics market: Application outlook and key takeaways
Fig. 19 U.S. Specialty Injectable Generics market: Application movement analysis & market share 2022 & 2030
Fig. 20 Oncology market, 2018 - 2030 (USD Million)
Fig. 21 Cardiovascular market, 2018 - 2030 (USD Million)
Fig. 22 CNS market, 2018 - 2030 (USD Million)
Fig. 23 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 24 Autoimmune Disorders market, 2018 - 2030 (USD Million)
Fig. 25 Others market, 2018 - 2030 (USD Million)
Fig. 26 U.S. Specialty Injectable Generics market: Distribution channel outlook and key takeaways
Fig. 27 U.S. Specialty Injectable Generics market: Distribution channel movement analysis & market share 2022 & 2030
Fig. 28 Hospital market, 2018 - 2030 (USD Million)
Fig. 29 Retail pharmacy market, 2018 - 2030 (USD Million)
Fig. 30 Others market, 2018 - 2030 (USD Million)
Fig. 31 Strategy Mapping

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.